


Solve-RD Code of Conduct

Version	V2.2	
Date / History of changes	05.07.2024 (V2.2)	Update Attachment 3 (Solve-RD Publication Policy)
	18.12.2020 (V2.1)	Update Attachment 3 (Solve-RD Publication Policy)
	19.06.2020 (V2)	Footnote added on page 3 (download from sftp server)
	22.01.2020 (V1)	
Authors	Holm Graessner (EKUT), Birte Zurek (EKUT), Ana Topf (UNEW), Sergi Beltran (CNAG-CRG), Lennart Johansson (UMCG), Martina Melovic (EKUT, legal council)	
Approved by GA	22.01.2020 (V1)	

Definitions

- **Investigator:** Individual data user affiliated to a Solve-RD beneficiary or associated partner.
- **Raw dataset:** exome or genome sequencing data, omics data, phenotype data from single individuals which have not been processed through an analysis pipeline.
- **Processed dataset:** data that are the result of raw data being processed through an analysis pipeline by Solve-RD or Solve-RD partners. It also includes analysis results.
- **Solve-RD Sandbox:** temporary secure compute environment / private 'cloud' for storage of data as well as tailored and *de novo* bioinformatics analysis in Solve-RD. The Solve-RD sandbox is composed of two parts: 1) an EGA box where raw data is being stored and 2) an European Bioinformatics Institute hosted analysis sandbox which can be used for data analysis. All data in the analysis sandbox (part 2 above) will be deleted on the completion of the Solve-RD project unless Union or Member State law requires storage of the data. Data in the EGA box (part 1 above) will be properly archived for the future at the EGA to enable controlled access distribution.

Contractual basis

The following is the Code of Conduct that the Investigator agrees to abide by as a user of the Solve-RD analysis sandbox. Failure to abide by any term within this Code of Conduct may result in revocation of approved access to any or all data obtained through the Sandbox.

Solve-RD comprises pseudonymised sensitive data of rare disease patients and their family members (phenotype data, metadata, raw datasets, and processed datasets) that are provided by contributing beneficiaries and associated partners. The contributing beneficiaries and associated partners are the primary data controllers of the datasets they contribute. Data shall not be processed, downloaded and/or used for any analysis unless the specific analysis/usage has been registered through the Solve-RD *Analysis Template* (see attachment 1) and the Investigator has been granted user rights for the Sandbox. Specifically, Investigators will work according to the following rules:

Principles

1. Investigator will adhere to the Solve-RD Data Sharing Policy¹ (see attachment 2).
2. Investigator will adhere to the Solve-RD Publication Policy² (see attachment 3).
3. Investigator acknowledges Solve-RD funding in any publication stemming from data processing of any Solve-RD data using the following wording: "The Solve-RD project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 779257."

Access to the Sandbox

¹ Latest version available here: <http://solve-rd.eu/results/presentations/>

² Latest version available here: <http://solve-rd.eu/results/presentations/>

4. Investigator's permission to access Solve-RD data is limited to all Investigators that have signed this Code of Conduct.
5. Investigator will refrain from downloading data to any location that has not been approved by Solve-RD³.
6. Approvals for downloading data from the Solve-RD Sandbox to secure local clusters will be granted by the Solve-RD Steering Committee upon application from Investigator. Record of all persons locally accessing the data must be kept by the Investigator who has been granted approval and shared with Solve-RD upon request.
7. Downloaded data will have to be deleted on the completion of the Solve-RD project unless Union or Member State law requires storage of the data. Investigator will confirm the deletion of downloaded data and respective processed data to the Solve-RD project office.
8. Investigator will report any inadvertent data release, breach of data security, or other data management incidents contrary to the terms of data access specified in this Code of Conduct to info@solve-rd.eu.

Data processing

9. Investigator will perform all analyses solely on the Sandbox, on approved local clusters ensuring data security or on a Solve-RD approved secure space.
10. Investigator will process datasets contained in the Solve-RD Sandbox solely in connection with an approved analysis project described in the Solve-RD Analysis Template (see attachment 1).
11. When data is downloaded from the Sandbox to a local cluster for processing locally, Investigator will ensure that all downloaded data as well as intermediate/output data generated through analysis/data usage, are solely accessible by the Investigator him or herself and their team.
12. Investigator agrees that the data may only be used for the permitted purpose to conduct the approved analysis/data usage.
13. Investigator is not allowed to inform the primary controller of the dataset about an incidental finding, unless the primary controller of that dataset explicitly requests this information from Investigator.
14. Investigator will provide the results of the analysis/data usage to the primary controller of the dataset as soon as the analysis results are available.
15. Investigator is aware that all activities with regards to processing data in the Sandbox and downloading data will be monitored at the level of individual researcher.
16. Investigator will make no attempt to identify or contact participants from whom these data were collected unless re-contact is appropriate for particular reasons. Such decision will be made by the Solve-RD SC. Participants will have the right to withdraw.

I read and understand the Solve-RD Code of Conduct as well as the Solve-RD Data Sharing Policy and Publication Policy. I declare that I will abide by it and will act accordingly. I understand that failure to adhere to the Code of Conduct will have repercussions for my role in Solve-RD.

Please, sign this Code of Conduct and send a scanned copy to birte.zurek@med.uni-tuebingen.de

³ Download of analysis result files from the DITF folders on the sftp server by DITF and WG members is allowed.

Attachment 1: Data analysis template (Version 2 | 12.03.2020)

Project Template for Usage and/or Analysis of data within Solve-RD⁴

Investigators	<i>Person responsible for the analysis project (WG lead)</i> <i>Other key personnel / external collaborators involved (WG members)</i>	
Affiliated institutions	<i>List all institutions involved</i>	
Email address of responsible investigator	<i>Address of responsible person</i>	
Date	<i>dd.mm.yyyy (date of application)</i>	
Title of the proposed project		
<i>Project Title</i>		
Brief description of the project		
Keywords	<i>Add max 5 keywords.</i>	
Specific aims	<i>State the aims of the project as specifically as possible.</i>	
Study design	<i>Describe the study design.</i>	
Cohort, clinical / OMICS data	<i>Summarise the data you will use/analyse.</i> <i>Describe inclusion criteria for cohort/data selection and approximate numbers if applicable.</i>	
Plans for analysis / use		
Required analysis resources	<i>Summarise the storage and/or compute capacity needed for the analysis.</i> <i>Clarify if you will do analyses in the sandbox and/or local cluster.</i>	
Download of data	Date of download:	<i>If applicable [dd.mm.yyyy]</i>
	Location of the secure local cluster where data is being stored:	<i>If applicable</i>
	Downloaded datasets:	<i>If applicable</i>

⁴ Please do only fill out the white fields.

End date	<i>Provide estimated date [dd.mm.yyyy] by when this project will be completed.</i>
Contributions	<i>Please list main contributors for this project (DITFs, specific groups etc.).</i>

Please fill in this template and send it to the DITF coordinators of all ERNs concerned and the Solve-RD coordination office (birte.zurek@med.uni-tuebingen.de). DITF coordinators will inform the respective data submitters of their DITF. If DITF coordinators deem the planned analysis as being not in accordance with the Solve-RD objectives and Data Sharing Policy, they will express their concerns to the WP2 leads Alex Hoischen and Sergi Beltran.

Attachment 2: Solve-RD Data Sharing Policy


Solve-RD Data Sharing Policy

Version	Final V7
Date	09.01.2020
Authors	EKUT: Holm Graessner, Tina Harmuth, Birte Zurek, Martina Melovic CNAG-CRG: Sergi Beltran ULEIC: Tony Brookes, UMCG: Morris Swertz
Approved by GA	22.01.2020

Definitions

- **Raw dataset:** exome or genome sequencing data in FASTQ or BAM format with corresponding phenotypic data in HPO format from a single individual.
- **Data collection:** multiple raw datasets from a single centre.
- **Processed dataset:** a raw dataset whose exome or genome sequencing data has been processed through the Solve-RD/RD-Connect variant calling analysis pipeline. It includes the variant calls, some metrics and the corresponding phenotypic information.
- **RD-Connect Genome-Phenome Analysis Platform (GPAP):** platform that enables collation, processing, analysis, interpretation and sharing of integrated genome and phenome datasets. The RD-Connect GPAP will only retain processed datasets (<https://platform.rd-connect.eu/>).
- **European Genome-phenome Archive (EGA):** storage facility that is used by the RD-Connect GPAP for storage of the raw datasets (<https://ega-archive.eu>).
- **Solve-RD analysis sandbox:** secure compute environment / private 'cloud' for tailored and *de novo* bioinformatics analysis. Data will be deleted after the Solve-RD analysis have been finalized that is at the latest two years after the end of the project (i.e. after December 31st 2024).
- **PhenoTips:** user friendly tool integrated in the RD-Connect GPAP to collate and store the phenotypic information from a dataset using ontologies and standards such as HPO, ORDO and OMIM (<https://platform.rd-connect.eu/>, <https://phenotips.org>).

Explanation figure of data sharing process



Most important points of Solve-RD data sharing policy

- All exome/genome and phenotypic data that will be collated in task 1.2 of Solve-RD will be submitted to the RD-Connect Genome-Phenome Analysis Platform (GPAP)
- All IT systems used in Solve-RD comply with the General Data Protection Regulation, GDPR (Regulation (EU) 2016/679)
- Options for uploading datasets include single dataset upload and bulk upload
- Specific data access stipulations for Solve-RD in GPAP:
 - All data submitters will be able to see which other users have accessed their submitted datasets and when
 - If justified Solve-RD data submitters can define longer embargo periods before data become accessible to other users

Upload of exome/genome and phenotypic data to the RD-Connect GPAP

All exome/genome and phenotypic data that will be collated in task 1.2 of Solve-RD will be submitted to the RD-Connect Genome-Phenome Analysis Platform, an IRDiRC recognised resource. This empowers the clinical

end-users and their research teams to analyse and interpret their own data and actively participate in solving cases rather than only handing it over to the project and waiting for results.

Where unsolved processed datasets from previous projects are already available in the platform, there will be an option to assign these to the Solve-RD project, while also keeping the assignment to the original project (if this is the case). An option to assign a new or existing dataset to a specific European Reference Network (ERN) will also be available.

Options for uploading

One raw dataset is considered to include both **phenotypic data** in the form of HPO terms and **exome/genome data** of a patient, preferentially in FASTQ format, although BAM files are also accepted.

There are two options for uploading datasets.

- i. **Data collections from centres that will upload fewer than 100 raw datasets:** raw datasets will be uploaded using the standard RD-Connect GPAP upload interface, which includes user friendly PhenoTips templates to enter the phenotypic information and user-friendly tables to upload the genomic data and metadata. An option to bulk upload the genomic data and metadata is also available.
- ii. **Data collection from centres that will upload 100 or more raw datasets:** in cooperation with CNAG-CRG in Barcelona there will be the opportunity to discuss a customised bulk upload option to facilitate uploading large data collections.

All sequencing data are submitted as raw data in FASTQ (or BAM) format and are processed through the same Solve-RD pipeline. The processed datasets will be stored in the platform for as long as it has a legitimate interest in doing so. (see below for storage of raw data at the EGA). Clinical interpretation of the data (final or temporary) can be entered in the RD-Connect platform but this is not a requirement at upload.

The raw data will not be stored in the European Genome-phenome Archive (see below) for longer than is necessary. Personal data will be processed fairly and lawfully in accordance with the EU General Data Protection Regulation 2016/679.

Data security and accessibility

RD-Connect pays strict attention to data quality and security and the data in the Platform meet high quality and safety standards. The RD-Connect registration process includes user validation as defined in the RD-Connect GPAP Code of Conduct (<https://rd-connect.eu/gpap-code-conduct>), which all users must confirm they accept. Additionally, the PI/group leads must sign the [Adherence Agreement](#).

Other computer systems used in Solve-RD will adhere to similar standards.

(i) Who can access the processed dataset/s in the RD-Connect Genome-Phenome Analysis Platform?

- Data submitters can request an embargo period for each of their datasets. During the embargo period the data is accessible only to the members from the submitter group and the Solve-RD user group. However, the members of the original submitter group can share it specifically with other group/s of users (from another PI/group lead).
- After the embargo period set by the submitter, datasets uploaded to the RD-Connect GPAP will become accessible to all authorised scientists and clinicians who have gone through the strict registration and verification process.

- The embargo period is considered to start at the moment a specific processed dataset (genomic plus phenotypic data) is made accessible to the dataset submitter.

(ii) Who can access Solve-RD processed datasets within the RD-Connect GPAP and under which conditions?

- Account registration: Every PI/group lead enrolled in Solve-RD or in a participating ERN will undergo the full RD-Connect registration process and will then enrol members of their team. All the users under the responsibility of one PI/group lead are assigned to the same user group and have the same user permissions but have different usernames and passwords to enable user-specific logs. In addition, every PI/group that will upload samples for Solve-RD and that is not a Solve-RD beneficiary will have to sign an association agreement with Solve-RD containing the Solve-RD Data Sharing Policy and Publication Policy.
- Solve-RD tagging of datasets: New datasets uploaded specifically for the Solve-RD project will be assigned to the Solve-RD project to allow project-wide sharing and monitoring. Pre-existing unsolved processed datasets can be added to the Solve-RD project (while also keeping the original project tag). Datasets must also be tagged with the name of the submitting European Reference Network (ERN) so that it is possible to follow numbers submitted per ERN.
- No embargo period within Solve-RD: Data become accessible to all other authorised Solve-RD users immediately after submission. Solve-RD users can analyse and query their own datasets as well as datasets submitted by other Solve-RD users.
- Access of Solve-RD datasets by other users of the RD-Connect Genome-Phenome Analysis Platform that are not part of Solve-RD:
 - i. Embargo periods of up to twelve months: As part of the online data submission process, Solve-RD users can easily define an embargo period of up to twelve months before data become accessible to other users of the RD-Connect Genome-Phenome Analysis Platform. Solve-RD users selecting an embargo period of up to six months will not be asked for any additional information, but Solve-RD data submitters requesting an embargo period between six and twelve months will be asked to type a short justification. RD-Connect has agreed to delegate approval of embargo periods between six and twelve months to the Solve-RD Steering Committee, which will only contact Solve-RD data submitters if the embargo period has been denied or more details are needed.
 - ii. Embargo periods longer than twelve months: depending on the origin and nature of data (for example if they are diagnostic data) Solve-RD users can request (in written form at the time of submission) an embargo period longer than twelve months before data become accessible to other users of the RD-Connect Genome-Phenome Analysis Platform. Requests longer than twelve months will require acceptance by the Solve-RD Steering Committee and by the RD-Connect GPAP Access Committee since they are considered non-compliant with IRDiRC principles for rapid data release. Retrospective requests for prolonged embargo periods are not possible.
- Access reports: within the RD-Connect GPAP data management portal, a dataset submitter is able to see which other users have accessed at which date a given dataset through a specific query on that dataset or through a general query.

(iii) What can users do with the data?

- During embargo: Datasets are only accessible to the submitter and the Solve-RD project members. Members from the submitter group can share specific datasets with other RD-Connect GPAP users. Users with access to the datasets will be able to discover, query, analyse, interpret and tag them. If the submitter group has opened the dataset to matchmaking through MatchMaker Exchange, internal RD-Connect users and external users across the globe performing a matchmaking query may be informed that there is a dataset containing a potential match, but the user cannot see the relevant dataset and must contact the submitter to find out more details or request sharing.
- After embargo: Datasets are accessible to the other authorised users within the RD-Connect GPAP, who will also be able to discover, query, analyse, interpret and tag them. The datasets also need to be specifically opened by the submitter group for matchmaking.
- Download of data: Direct download of full datasets is not possible at any time. Download of search results will be restricted to the user group that submitted the dataset and users with whom it may have been specifically shared by the submitter group.

(iv) Data security

Data is stored in a computer cluster with a restricted access policy, limited internet access and daily backups. Databases are using distributed filesystems, limiting the risk of physical attacks. All communications are encrypted. Security of the platform was audited in October 2017 with no major risks being identified. Platform requests and user actions are safely logged for audit purposes. Documentation and procedures are currently being adapted for the new General Data Protection Regulation, GDPR (Regulation (EU) 2016/679).

Matchmaking and discovery

The RD-Connect GPAP is integrated in the Beacon Network (<https://beacon-network.org>), a project by the Global Alliance for Genomics and Health (GA4GH).

RD-Connect participates in MatchMaker Exchange (MME, <http://www.matchmakerexchange.org>) and MME is functional for internal GPAP queries and bi-lateral queries to PhenomeCentral. Bi-lateral queries to DECIPHER are being implemented. Additionally, patient profiles can be pushed to PhenomeCentral (<https://www.phenomecentral.org>) from the RD-Connect GPAP PhenoTips instance by the data submitters. The dataset submitter must specifically enable matchmaking at the time of submission or in the data management portal. This permission can also be enabled or disabled at any later stage. Increasing powerful and precise forms of matchmaking will be developed by Solve-RD in conjunction with GA4GH and others, to enable ever more sophisticated dataset discovery and matchmaking with more options for data protection. Dataset submitters will have to specifically enable the datasets for new forms of discovery and/or matchmaking outside the RD-Connect GPAP and/or Solve-RD if they are less restrictive than the current MME v1.

Patient security and confidentiality

To protect patient privacy, explicitly identifiable patient information is never submitted to the Platform. The submitting clinician stores the data in the manner appropriate for their own centre and links it at a secure local level to the unique RD-Connect IDs. Patient identities are therefore not stored on the Platform and cannot be accessed by Platform users. Only the researcher who submitted the data has the key to identify the IDs corresponding to his/her data.

(v) Return of results

Solve-RD is a research project and as such cannot ensure the quality standards required for genetic diagnostics. It is thus the responsibility of the clinician/researcher who submitted the data and who is the only one who has access to the patient and family to validate any novel genes and to return the results to the patient and her/his family (depending on the consent given).

It is possible that other GPAP users identify genetic variants in sequencing data submitted by Solve-RD partners. These variants may explain the cause of the patients' disease but they may also be completely unrelated – so called 'incidental findings'. Some clinicians don't want to be informed about such incidental findings. We have thus put a system in place where the data submitter can indicate for every patient if they DO NOT WANT to be notified about (forced) incidental findings: "This patient has not consented to be notified about incidental findings and I don't want to be contacted regarding incidental findings on this patient". The system to contact other users, which would basically send an email to both data submitter and the "data analyst" to put them in contact on a certain experiment, includes this message so that the "data analyst" would know that he/she should NOT contact the submitter for any findings which are not related to the patients' disease.

(vi) Storage of raw data in the European Genome-phenome Archive (EGA)

The raw data will not be kept for longer than is necessary for the purposes at the [European Genome-phenome Archive \(EGA\)](#), a secure, controlled-access repository. The EGA serves as an archive for publications as well as data on several levels, including the raw data (to allow future reanalysis using other algorithms) and the genotype calls (information about pathogenic genetic variants) provided by the data submitters.

The EGA provides the necessary security required to control access to the data and maintain patient confidentiality. Data can be accessed only by authorised researchers and clinicians. In all cases, data access decisions are made not by the EGA but by an appropriate Data Access Committee, which can be the person or group submitting the data.

Data must be submitted to the EGA at the latest by the end of Solve-RD. At the time of uploading a dataset to the RD-Connect GPAP, the user can indicate if the dataset is already available at the EGA and provide the corresponding reference number. For datasets not yet available at the EGA, the CNAG-CRG will broker the submission to the EGA of the data and metadata uploaded to the RD-Connect GPAP. The original data submitter will be responsible for making decisions regarding the future access to their datasets.

(vii) Solve-RD publications - notification and authorship policy with regard to shared data

All Solve-RD publications are acknowledged to be based on the fundamental principles of open scientific collaboration, reciprocity, attribution and benefit sharing. For any publication resulting from work carried out using data shared or generated through Solve-RD (e.g. for identifying a novel gene), including where data has been accessed through the RD-Connect Genome-Phenome Analysis Platform, the Analysis Sandbox or future Solve-RD systems, the authors should in all cases acknowledge and give appropriate authorship positions to all relevant parties in line with best practice for acknowledgement of scientific contribution including submission of the primary data (also see the [Solve-RD Publication Policy](#)).

Examples and further principles are described below.

- 1. A publication arising from research in which the party leading the publication ("the PI team") is primarily analysing their own submitted data (example: novel gene discovery by a submitter analysing their own patient cohorts in the RD-Connect GPAP):**
 - i. Where a publication only includes data and hypotheses from the PI's own research group, key authorship positions may be held by this group, but the software, tools and resources made use

of for the research should be duly acknowledged and referenced in line with the policies for those resources (e.g. see RD-Connect GPAP policy below). Where justified, individuals supporting the bioinformatics analysis or platforms may be approached for co-authorship based on individual scientific contribution.

- ii. Where a publication has involved the use or analysis of data from additional submitters, these submitters should be contacted as soon as possible ahead of publication and invited to provide input as co-authors. The PI team is strongly encouraged to share key authorship positions with other teams that have brought in similar intellectual input and/or fundamental data (e.g. “a second family”). Acknowledgement of bioinformatics support should also be considered as in (i) above.

2. A publication arising from the analysis of data where the party generating the hypothesis and carrying out the analysis is not themselves the data submitter (example: reanalysis of data by a Solve-RD bioinformatics group that did not submit the data or see the patients):

- i. Submitters of the data used for the analysis should be contacted as soon as possible ahead of publication and invited to provide input as co-authors. The PI team is strongly encouraged to share key authorship positions with the submitting teams based on the value and amount of data contributed to the publication. If the primary data is the key to discovery, a key authorship position should be discussed with the owner of the primary data.
- ii. Where a publication makes use of data from a large number of submitters or transversal analysis of the Solve-RD cohort, a group authorship for Solve-RD (see [Solve-RD Publication Policy](#)) should be considered in order to acknowledge the role of all data submitters equally.

All data access through the RD-Connect Genome-Phenome Analysis Platform is monitored automatically by the system and all other data access for other Solve-RD activities is only to named individuals within the Solve-RD consortium, therefore any breach of the publication policy will be monitored and flagged up to the Solve-RD Steering Committee.

Solve-RD funding acknowledgement

Any publications arising from Solve-RD project funding should acknowledge it in the following way:

“This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD).”

RD-Connect GPAP acknowledgement

In addition to authorship positions as described above, any publications that arise from the use of the RD-Connect Genome Phenome Analysis Platform should acknowledge it in the following way:

“This study makes use of data shared/provided through RD-Connect, which received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.”

In addition, the following paper should be cited:

Lochmüller H & Badowska D, Thompson R, Knoers N, Aartsma-Rus A, Gut I, Wood L, Harmuth T, Durudas A, Graessner H, Schaefer F & Rieß O. RD-Connect, NeurOmics and EUREnOmics: Collaborative European Initiative for Rare Diseases. *European Journal of Human Genetics*. 2018.

ERN acknowledgement

Any publications with contributions from ERNs should acknowledge involved ERNs in the following way:

“This study was supported by the European Reference Network(s) [add ERN names] (https://ec.europa.eu/health/ern/networks_en).”

Attachment 3: Solve-RD Publication Policy

Solve-RD Publication Policy

Version	V3.1	
Date / History of changes	5 July 2024 (V3.1)	V3.1: Update Annex I (Solve-RD author lists)
	8 November 2023 (V3)	V3: Addition of sections 1-3, update section 4 and 8
	16 February 2022 (V2.2)	V2.2: Update Annex I (Solve-RD author list)
	18 December 2020 (V2.1)	V2.1: Update Annex I (Solve-RD author list)
Authors	18 April 2018 (V2)	
	Holm Graessner, Tina Harmuth, Birte Zurek, Kornelia Ellwanger	
Approved by GA	05.02.2024 (V3)	

1 Solve-RD Publication Board

Solve-RD established a Publication Board. The Publication Board is chaired by Holm Graessner and engages all WP leads and is open for interested DITF and WG leads to join. The Publication Board shall strategically plan publications and shall ensure transparent communication about planned Solve-RD publications. The Publication Board shall also provide advice on authorship discussions.

2 Solve-RD publication tiers

The Publication Board defined **three tiers of Solve-RD publications** in terms of scope and coordination requirements. The three-tier model has been approved by the Solve-RD Steering Committee on 16 Feb 2021.

Tier 1 “flagship” publications

- Require input from the entire Solve-RD consortium and central coordination
- ERN/DITF and/or WP-level (or even cross WP) coordination/lead required
- Example: massive re-analysis of all existing WES/WGS data

Tier 2 „central“ Solve-RD publications

- Requires coordination within ERN/DITF or DITF/WG
- Example: individual manuscript of re-analysis effort of a WG; or individual ERN yield/new phenotype/new gene(s)

Tier 3 „local“ Solve-RD publications

- Individual solved cases/disease
- Case reports

3 Solve-RD fairness principles to determine authorship

The Publication Board defined the following **principles to determine authorship**:

(1) Authorship reflects (scientific) contribution

- Infrastructure and support roles (such as clinicians contributing cases or infrastructure enabling joint analysis) will be taken into consideration, too.
 - (Governance) role in the project should not define authorship (position).
- (2) Fair and justified designation of authors
- Designation of authors will be based on submitted analysis projects and in line with the Solve-RD Publication Policy.
 - Prominent authors shall take responsibility for the manuscript.
 - Both “fairness towards the consortium” and “fairness towards individuals” will be taken into account, however, individual contribution has to be appreciated foremost.

Proposed process to determine authorship (for tier 1 publications):

- Manuscript leads propose authorship positions based on contribution taking into account the Solve-RDs fairness principles.
- All authors and contributing Solve-RD sub-structures (DATF-WGs, DITFs, etc.) are being informed and explicit agreement is requested.
- Proposal of authorship positions is being run by the Publication Board. Only in case of serious issues the SC is being involved. Sub-structures (e.g. DITF) propose and harmonise respective authorship rules.

4 ‘Solve-RD consortium’ as an author and additional Solve-RD corporate authorship lists

An affiliation list has been created and is regularly being updated containing all members of the Solve-RD consortium and associated partners (see Annex I). This list determines the Solve-RD author (‘Solve-RD consortium’). Additional authorship lists of Solve-RD subgroups (i.e. for ERN-specific Data Interpretation Task Forces (DITF)) have been created and contain all Solve-RD partners contributing to the respective subgroup.

The ‘Solve-RD consortium’ author list and all additional Solve-RD corporate authorship lists are administered and regularly updated by the project management team (lead: Holm Graessner).

‘Solve-RD consortium’ as an author shall be used for all publications that require input from the entire Solve-RD consortium (Tier 1).

Other Solve-RD corporate authorship lists will be used for publications that cover the work or contributions from the respective groups.

For all publications including ‘Solve-RD consortium’ or Solve-RD corporate authorship lists as an author, the responsible authors shall contact the project management office. The management office provides the most recent version of the respective list, provides advice for the use and support for appropriate formatting of the authorship lists considering the requirements of the respective journal and publisher. The management office is responsible to inform all list authors about the planned publication that makes use of the corporate author list.

5 Notification and authorship policy with regard to shared data

All Solve-RD publications are acknowledged to be based on the fundamental principles of open scientific collaboration, reciprocity, attribution and benefit sharing. For any publication resulting from work carried out using data shared or generated through Solve-RD (e.g. for identifying a novel gene), including where data has been accessed through the RD-Connect Genome-Phenome Analysis Platform, the authors should in all

cases acknowledge and give appropriate authorship positions to all relevant parties in line with best practice for acknowledgement of scientific contribution including submission of the primary data.

Examples and further principles are described below.

3. A publication arising from research in which the party leading the publication (“the PI team”) is primarily analysing their own submitted data (example: novel gene discovery by a submitter analysing their own patient cohorts in the RD-Connect GPAP):

- iii. Where a publication only includes data and hypotheses from the PI’s own research group, key authorship positions may be held by this group, but the software, tools and resources made use of for the research should be duly acknowledged and referenced in line with the policies for those resources (e.g. see RD-Connect GPAP policy below). Where justified, individuals supporting the bioinformatics analysis or platforms may be approached for co-authorship based on individual scientific contribution.
- iv. Where a publication has involved the use or analysis of data from additional submitters, these submitters should be contacted as soon as possible ahead of publication and invited to provide input as co-authors. The PI team is strongly encouraged to share key authorship positions with other teams that have brought in similar intellectual input and/or fundamental data (e.g. “a second family”). Acknowledgement of bioinformatics support should also be considered as in (a) above.

4. A publication arising from the analysis of data where the party generating the hypothesis and carrying out the analysis is not themselves the data submitter (example: reanalysis of data by a Solve-RD bioinformatics group that did not submit the data or see the patients):

- iii. Submitters of the data used for the analysis should be contacted as soon as possible ahead of publication and invited to provide input as co-authors. The PI team is strongly encouraged to share key authorship positions with the submitting teams based on the value and amount of data contributed to the publication. If the primary data is the key to discovery, a key authorship position should be discussed with the owner of the primary data.
- iv. Where a publication makes use of data from a large number of submitters or transversal analysis of the Solve-RD cohort, a group authorship for Solve-RD should be considered in order to acknowledge the role of all data submitters equally.

All data access through the RD-Connect genome-phenome analysis platform is monitored automatically by the system and all other data access for other Solve-RD activities is only to named individuals within the Solve-RD consortium, therefore any breach of the publication policy will be monitored and flagged up to the Solve-RD Steering Committee.

6 Confirmation of paper by Solve-RD Consortium

During the project and for a period of one (1) year after the project, every paper that is published with affiliation of Solve-RD or includes data produced or collated within Solve-RD has to be confirmed by the Solve-RD Consortium. The procedure is defined in Article 29.1 of the Solve-RD Grant Agreement and Article 8.4.2 of the Solve-RD Consortium Agreement. All Parties and associated partners (including associated ERNs) are obliged to follow this procedure:

Prior notice of any planned publication shall be given to the other Parties at least 45 calendar days before the intended date of publication. Any objection to the planned publication following the above notification shall be made in accordance with the Grant Agreement in writing to the Coordinator and to the Party or

Parties proposing the dissemination within thirty (30) calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted.

An objection is justified if (a) the protection of the objecting Party's Results or Background would be adversely affected and/or (b) the objecting Party's legitimate academic or commercial interests in relation to the Results or Background would be significantly harmed.

The objection has to include a precise and reasonable request for necessary modifications, it being specified that any such modifications shall not harm the scientific content of the proposed publication or communication.

If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion. The objecting Party can request a publication delay of not more than 90 calendar days from date of submission to the other Parties. After 90 calendar days the publication is permitted provided that Confidential Information of the objecting Party has been removed from the Publication and all reasonable modifications of the objecting Party have been implemented within the Publication as indicated by the objecting Party.

A decision has to be made and communicated within four weeks after submission of the publication draft (author list and abstract) to the Steering Committee.

7 Parallel Analysis of submitted data at centres

The Publication Board has to be informed if data sets that were submitted to Solve-RD for central analysis lead to publications based on separate (in-house) analysis.

8 Acknowledgements

Solve-RD funding acknowledgement

Any publications arising from Solve-RD project funding must be published Open Access and acknowledge EU funding in the following way:

“This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 779257 (Solve-RD).”

RD-Connect GPAP acknowledgement

Authors should acknowledge the RD-Connect GPAP if tools, services or data provided by the platform have enabled or have contributed to research targeted for scientific publication.

RD-Connect GPAP should be acknowledged using the following wording:

“This study makes use of data and tools shared/provided through the RD-Connect GPAP, which received funding originally from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. 305444.”

In addition, the following paper should be cited:

Laurie S., Piscia D., Matalonga L., Corvo A., Garcia C., et al. The RD-Connect Genome-Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases. *Human Mutation* 2022 febr. 17. doi: <https://doi.org/10.1002/humu.24353>

Where appropriate, the RD-Connect GPAP should also be explicitly mentioned in the “Materials and methods” and/or “Results” section.

ERN acknowledgement

Any publications with contributions from ERNs should acknowledge involved ERNs in the following way:

“This study was supported by the European Reference Network(s) [add ERN names] (https://ec.europa.eu/health/ern/networks_en).”

Annex I: Solve-RD author lists

'Solve-RD consortium'

EKUT: Olaf Riess^{1, 2}, Tobias B. Haack^{1, 2}, Holm Graessner^{1, 2}, Stephan Ossowski^{1, 3, 4}, Birte Zurek^{1, 2}, Kornelia Ellwanger^{1, 2}, German Demidov¹, Marc Sturm¹, Joohyun Park¹, Leon Schütz¹, Julia M. Schulze-Hentrich^{1, 5}, Rebecca Schüle^{6, 7}, Jishu Xu^{6, 8}, Melanie Kellner^{6, 8}, Baptist Resch⁷, Ingrid Kolen⁷, Matthis Synofzik^{6, 8}, Carlo Wilke^{6, 8}, Andreas Träschütz^{6, 8}, Danique Beijer⁹, Peter Heutink^{6, 8}, Ludger Schöls^{6, 8}, Holger Hengel^{6, 8}, Holger Lerche¹⁰, Christian Boßelmann¹⁰, Josua Kegele¹⁰, Robert Lauerer-Braun¹⁰, Stephan Lauxmann¹⁰

RUMC: Han Brunner¹¹⁻¹³, Hans Scheffer^{11, 12}, Nicoline Hoogerbrugge^{11, 14}, Alexander Hoischen^{11, 14, 15}, Peter A.C. 't Hoen^{14, 16}, Lisenka E.L.M. Vissers^{11, 12}, Christian Gilissen^{11, 14}, Wouter Steyaert^{11, 14}, Karolis Sablauskas¹¹, Richarda M. de Voer^{11, 14}, Erik-Jan Kamsteeg¹¹, Bart van de Warrenburg^{12, 17}, Nienke van Os^{12, 17}, Iris te Paske^{11, 14}, Erik Janssen^{11, 14}, Elke de Boer^{11, 12}, Marloes Steehouwer¹¹, Burcu Yaldiz¹¹, Kornelia Neveling¹¹, Bart van der Sanden¹¹, Lydia Sagath¹¹, Tjitske Kleefstra^{11, 12}

University of Leicester: Anthony J. Brookes¹⁸, Spencer Gibson¹⁸, Umar Riaz¹⁸, Greg Warren¹⁸, Sai Anuhya Nalagandla¹⁸, Yunze Patrick Wang¹⁸, Deepthi Sukumaran¹⁸, Sadegh Abadijoui¹⁸

UNEW: Ana Töpf¹⁹, Volker Straub¹⁹, Chiara Marini Bettolo¹⁹, Jordi Diaz Manera¹⁹, Sophie Hambleton²⁰, Karin Engelhardt²⁰

MUH: Jill Clayton-Smith^{21, 22}, Siddharth Banka^{21, 22}, Elizabeth Alexander²², Adam Jackson^{21, 22}

DIJON: Laurence Faivre²³⁻²⁷, Christel Thauvin²³⁻²⁷, Antonio Vitobello²⁵, Anne-Sophie Denommé-Pichon²⁵, Yannis Duffourd^{25, 26}, Ange-Line Bruel²⁵, Victor Couturier²⁵

CNAG-CRG: Sergi Beltran^{28, 29}, Ivo Glynne Gut^{28, 30}, Steven Laurie^{28, 30}, Davide Piscia²⁸, Leslie Matalonga^{28, 30}, Anastasios Papakonstantinou^{28, 30}, Gemma Bullich^{28, 30}, Alberto Corvo^{28, 30}, Marcos Fernandez-Callejo^{28, 30}, Carles Hernández^{28, 30}, Daniel Picó^{28, 30}, Ida Paramonov^{28, 30}, Anna Esteve Codina^{28, 31}, Marc Dabad²⁸, Marta Gut^{28, 31}, Emanuele Raineri²⁸, Hanns Lochmüller^{28, 30}

EURORDIS: Gulcin Gumus³², Virginie Bros-Facer³³

INSERM-Orphanet: Ana Rath³⁴, Marc Hanauer³⁴, David Lagorce³⁴, Oscar Hongnat³⁴, Maroua Chahdil³⁴, Caterina Lucano³⁴, Emeline Lebreton³⁴

INSERM-ICM: Giovanni Stevanin^{35, 36}, Alexandra Durr^{35, 37}, Claire-Sophie Davoine³⁵, Léna Guillot-Noel³⁵, Anna Heinzmann^{35, 37}, Giulia Coarelli^{35, 37}

INSERM-CRM: Gisèle Bonne³⁸, Teresinha Evangelista^{38, 39}, Valérie Allamand³⁸, Isabelle Nelson³⁸, Rabah Ben Yaou³⁸⁻⁴⁰, Corinne Metay^{38, 41}, Bruno Eymard^{38, 39}, Enzo Cohen³⁸, Antonio Atalaia³⁸, Tanya Stojkovic^{38, 39}

Univerzita Karlova: Milan Macek Jr.⁴², Marek Turnovec⁴², Dana Thomasová⁴², Radka Pourová Kremlíková⁴², Vera Franková⁴², Markéta Havlovicová⁴², Lukáš Ryba⁴², Petra Lišková^{43, 44}, Pavla Doležalová⁴⁵, Alice Krebsová⁴⁶

EMBL-EBI: Helen Parkinson⁴⁷, Thomas Keane⁴⁷, Mallory Freeberg⁴⁷, Coline Thomas⁴⁷, Dylan Spalding^{47, 48}

Jackson Laboratory: Peter Robinson^{49, 50}, Daniel Danis⁴⁹

KCL: Glenn Robert⁵¹, Alessia Costa⁵²

UCL-IoN: Mike Hanna⁵³, Henry Houlden⁵⁴, Mary Reilly⁵³, Jana Vandrovčova⁵⁴, Stephanie Efthymiou⁵⁴, Heba Morsy^{54, 55}, Elisa Cali⁵⁴, Francesca Magrinelli⁵⁶, Sanjay M. Sisodiya⁵⁷, Ravishankara Bellampalli⁵⁷, Patrick Moloney⁵⁷, Jonathan Rohrer⁵⁸

UCL-ICH, Francesco Muntoni^{59, 60}, Irina Zaharieva⁵⁹, Anna Sarkozy⁵⁹, Luke Perry^{59, 60}, Veronica Pini⁵⁹, Juliane Müller⁵⁹

Universiteit Antwerpen: Vincent Timmerman^{61, 62}, Jonathan Baets^{63, 64}, Geert de Vries^{62, 63}, Jonathan De Winter⁶²⁻⁶⁴, Peter de Jonghe^{62, 64}, Liedewei Van de Vondel⁶¹⁻⁶³, Willem De Ridder⁶²⁻⁶⁴, Sarah Weckhuysen⁶³⁻⁶⁵, Hannah Stamberger^{64, 65}, Charissa Millevvert^{64, 65}, Noor Smal⁶⁵

Uni Naples/Telethon UDP: Vincenzo Nigro^{66, 67}, Manuela Morleo^{66, 67}, Michele Pinelli⁶⁷, Sandro Banfi^{66, 67}, Annalaura Torella^{66, 67}, Roberta Zeuli⁶⁶, Mariateresa Zanobio⁶⁶, Giulio Piluso⁶⁶

UNIFE: Alessandra Ferlini⁶⁸, Rita Selvatici⁶⁸, Francesca Gualandi⁶⁸, Stefania Bigoni⁶⁸, Marcella Neri⁶⁸

UKB: Stefan Aretz^{69, 70}, Isabel Spier^{69, 70}, Anna Katharina Sommer⁶⁹, Sophia Peters⁶⁹

IPATIMUP: Carla Oliveira⁷¹⁻⁷³, Jose Garcia-Pelaez^{71, 72}, Rita Barbosa-Matos^{71, 72}, Celina São José^{71, 72}, Marta Ferreira^{71, 72}, Irene Gullo⁷¹⁻⁷⁴, Susana Fernandes⁷⁵, Luzia Garrido⁷⁴, Pedro Ferreira^{71, 72, 76}, Fátima Carneiro⁷¹⁻⁷⁴

UMCG: Morris A Swertz⁷⁷, Lennart Johansson⁷⁷, Joeri K van der Velde⁷⁷, Gerben van der Vries⁷⁷, Pieter B Neerincx⁷⁷, Dieuwke Roelofs-Prins⁷⁷, David Ruvolo⁷⁷, Marielle van Gijn^{78, 79}

Kristin M Abbott⁷⁸, Wilhemina S Kerstjens Frederikse⁷⁸, Eveline Zonneveld-Huijssoon⁷⁸

Charité: Sebastian Köhler⁸⁰

SHU: Alison Metcalfe^{51, 81}, Richard Moore⁸²

APHP: Alain Verloes^{83, 84}, Séverine Drunat^{83, 84}, Delphine Heron^{85, 86}, Cyril Mignot^{85, 87}, Boris Keren⁸⁵, Jean-Madeleine de Sainte Agathe⁸⁵

Associated Partners

Rami Abou Jamra⁸⁸, Marc Abramowicz^{89, 90}, Özge Aksel Kiliçarslan⁹¹, Nicholas Allen⁹², Francisco Javier Alonso García de la Rosa⁹³, Simona Balestrini⁹⁴, Peter Balicza⁹⁵, Tobias Bartolomaeus⁸⁸, Ayşe Nazlı Başak⁹⁶, Laura Batlle Masó^{97, 98}, David Beeson⁹⁹, Valerie Benoit¹⁰⁰, Katherine Benson¹⁰¹, Eva Bermejo Sánchez⁹³, Emilia K. Bijlsma¹⁰², Elke Bogaert¹⁰³, Mara Bourbouli¹⁰⁴, Kaan Boztug¹⁰⁵⁻¹⁰⁹, Sylvain Brohée¹⁰⁰, Susan Byrne¹¹⁰⁻¹¹², Andrés Caballero Garcia de Oteyza^{113, 114}, Gabriel Capella^{115, 116}, Evelina Carpancea¹¹⁷, Gianpiero Cavalleri^{101, 110, 118}, Ana Cazorro-Gutiérrez¹¹⁹, Patrick F. Chinnery^{120, 121}, Maria-Roberta Cilio¹¹⁷, Andrea Ciolfi¹²², Kristl Claeys^{123, 124}, Roger Colobran¹²⁵⁻¹²⁷, Isabell Cordts¹²⁸, Judith Cossins⁹⁹, Karin Dahan^{100, 129}, Bruno Dallapiccola¹²², Norman Delanty^{101, 110, 130}, Christel Depienne^{131, 132}, Chantal Depondt¹³³, Bart Dermaut^{103, 134, 135}, Marcus Deschauer¹²⁸, Julie Desir¹⁰⁰, Anne Destrée¹⁰⁰, Minas Drakos¹⁰⁴, Sarah Duerinckx¹³³, Berta Estevez^{136, 137}, Athanasios Evangelidou¹³⁸, Chiara Fallerini^{139, 140}, Marco Ferilli¹²², Simone Furini^{139, 140}, Julien Gagneur¹⁴¹⁻¹⁴³, Hamidah Ghani^{101, 110, 118}, Marie Greally^{101, 110, 144}, Bodo Grimbacher^{114, 145-148}, Renzo Guerrini¹⁴⁹, Peter Hackman¹⁵⁰, Matthias Haimel¹⁰⁵⁻¹⁰⁷, Eva Hammar Bouveret⁸⁹, Dimitri Hemelsoet^{134, 151}, Rebecca Herzog^{152, 153}, Mariette J.V. Hoffer¹⁰², Elke Holinski-Feder¹⁵⁴, Rita Horvath¹²⁰, Manon Huibers¹⁵⁵, Michele Iacomino^{156, 157}, Mridul Johari¹⁵⁰, Elisabeth Kapaki¹⁵⁸, Deniz Karadurmus¹⁰⁰, Mert Karakaya¹⁵⁹⁻¹⁶², Evgenia Kokosalı¹⁰⁴, Christian Korff¹⁶³, Leon Krass¹⁴¹⁻¹⁴³, Didier Lacombe¹⁶⁴, Andreas Laner¹⁶⁵, Helen Leavis¹⁶⁶, Damien Lederer¹⁶⁷, Elsa Leitão¹³¹, Hanns Lochmüller^{91, 168, 169}, Katja Lohmann¹⁷⁰, Estrella López Martín⁹³, Rebeka Luknárová¹⁴¹, Alfons Macaya^{119, 171}, Sivasankar Malaichamy⁹¹, Anna Marcé-Grau¹¹⁹, Beatriz Martínez Delgado⁹³, Sandrine Mary¹⁶⁷, Frédéric Masclaux⁸⁹, Lambros Mathioudakis¹⁰⁴, Ales Maver¹⁷², Patrick May¹⁷³, Isabelle Maystadt^{100, 174}, Davide Mei⁹⁴, Christian Mertes^{141, 142}, Colombine Meunier¹⁰⁰, Maria Judit Molnar⁹⁵, Olivier Monestier¹⁰⁰, Stéphanie Moortgat¹⁰⁰, Alexander Münchau^{152, 175}, Francina Munell¹¹⁹, Andrés Nascimento Osorio^{136, 176, 177}, Daniel Natera de Benito^{136, 176, 177}, Mary O Reghan¹¹², Catarina Olimpio^{120, 178}, Elena Parrini⁹⁴, Martje Pauly^{152, 170}, Belén Pérez-Dueñas¹¹⁹, Borut Peterlin¹⁷², Konrad Platzer⁸⁸, Kiran Polavarapu⁹¹, Bruce Poppe^{103, 134, 135}, Manuel Posada De la Paz⁹³, Flavia Privitera^{139, 140}, Francesca Clementina Radio¹²², Thiloka Ratnaike¹⁷⁹, Alessandra

Renieri^{139, 140, 180}, Antonella Riva^{156, 181}, Caroline Rooryck¹⁶⁴, Andreas Roos^{91, 182}, Claudia A.L. Ruivenkamp¹⁰², Andreas Rump^{183, 184}, Gijs W.E. Santen¹⁰², Marco Savarese¹⁵⁰, Marcello Scala^{181, 185}, Katherine Schon^{120, 178}, Evelin Schröck¹⁸³, Nika Schuermans^{103, 134, 135}, Paolo Scudieri^{156, 181}, Martha Spilioti¹⁸⁶, Verena Steinke-Lange¹⁵⁴, Pasquale Striano^{181, 187}, Yves Sznajer¹⁸⁸, Marco Tartaglia¹²², Rachel Thompson⁹¹, Aurelien Trimouille¹⁸⁹, Bjarne Udd^{150, 190, 191}, Paolo Uva¹⁵⁷, Laura Valle^{115, 116}, Lars van der Veken¹⁵⁵, Roxane van Heurck⁸⁹, Joris van Montfrans¹⁹², Erika Van Nieuwenhove¹⁹², Hannah Verdin¹⁰³, David Webb¹¹², Brunhilde Wirth¹⁵⁹⁻¹⁶², Vicente A. Yépez¹⁴¹, Ioannis Zaganas¹⁰⁴, Federico Zara^{156, 181}, Kristina Zguro^{139, 140}.

Affiliations

1. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
2. Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.
3. NGS Competence Center Tübingen (NCCT), University of Tübingen, Tübingen, Germany.
4. Institute for Bioinformatics and Medical Informatics (IBMI), University of Tübingen, Tübingen, Germany.
5. Department of Genetics/Epigenetics, Faculty NT, Saarland University, Saarbrücken, Germany.
6. Department of Neurodegeneration, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
7. Division of Neurodegenerative Diseases and Movement Disorders, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
8. German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
9. Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
10. Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
11. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
12. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
13. Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, the Netherlands.
14. Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
15. Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands.
16. Center for Molecular and Biomolecular Informatics, Radboud University Medical Center, Nijmegen, the Netherlands.
17. Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
18. Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.
19. John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
20. Primary Immunodeficiency Group, Translational and Clinical Research Institute, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
21. Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK.
22. Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
23. Dijon University Hospital, Genetics Department, Dijon, France.
24. Dijon University Hospital, Centre of Reference for Rare Diseases: Development disorders and malformation syndromes, Dijon, France.
25. Inserm - University of Burgundy-Franche Comté, UMR1231 GAD, Dijon, France.
26. Dijon University Hospital, FHU-TRANSLAD, Dijon, France.

27. Dijon University Hospital, GIMI institute, Dijon, France.
28. Centro Nacional de Análisis Genómico (CNAG), C/Baldiri Reixac 4, 08028 Barcelona, Spain.
29. Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona (UB), Barcelona, Spain.
30. Universitat de Barcelona (UB), Barcelona, Spain.
31. Universitat Pompeu Fabra (UPF), Barcelona, Spain.
32. EURORDIS-Rare Diseases Europe, Sant Antoni Maria Claret 167 - 08025 Barcelona, Spain.
33. EURORDIS-Rare Diseases Europe, Plateforme Maladies Rares, 75014 Paris, France.
34. INSERM, US14 - Orphanet, Plateforme Maladies Rares, 75014 Paris, France.
35. Institut du Cerveau, INSERM U1127, CNRS UMR7225, Sorbonne university, Paris, France
36. INCIA, EPHE, CNRS UMR5287, Bordeaux university, Bordeaux, France.
37. Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
38. Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, F-75013 Paris, France.
39. AP-HP, Centre de Référence de Pathologie Neuromusculaire Nord, Est, Ile-de-France, Institut de Myologie, G.H. Pitié-Salpêtrière, F-75013 Paris, France.
40. Institut de Myologie, Equipe Bases de données, G.H. Pitié-Salpêtrière, F-75013 Paris, France.
41. AP-HP, Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, G.H. Pitié-Salpêtrière, F-75013 Paris, France.
42. Department of Biology and Medical Genetics, Charles University Prague-2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
43. Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
44. Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
45. Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
46. Department of Cardiology - Institute of Clinical and Experimental Medicine and Department of Biology and Medical Genetics - 2nd Faculty of Medicine Charles University, Prague, Czech Republic
47. European Bioinformatics Institute, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom.
48. CSC-IT Center for Science, 02101 Espoo, Finland.
49. Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
50. Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
51. Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College, London, UK.
52. Society and Ethics Research, Connecting Science, Wellcome Genome Campus, Hinxton, UK.
53. MRC Centre for Neuromuscular Diseases and National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, London, UK.
54. Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
55. Department of Human Genetics, Medical Research Institute, Alexandria University, Egypt.
56. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, WC1N 3BG.
57. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
58. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
59. Dubowitz Neuromuscular Centre, UCL Great Ormond Street Hospital, London, UK.
60. NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom.

61. Peripheral Neuropathy Research Group, University of Antwerp, Antwerp, Belgium.
62. Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium.
63. Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium.
64. Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium.
65. VIB-CMN, Applied and Translational Neurogenomics Group.
66. Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Italy.
67. Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
68. Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Italy.
69. Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
70. Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
71. i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
72. IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.
73. Faculty of Medicine, University of Porto, Portugal.
74. CHUSJ, Centro Hospitalar e Universitário de São João, Porto, Portugal.
75. Department of Genetics, Faculty of Medicine, University of Porto, Portugal.
76. Faculty of Sciences, University of Porto, Portugal.
77. Department of Genetics, Genomics Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
78. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
79. Department of Human Genetics, Amsterdam UMC, University of Amsterdam, the Netherlands.
80. Ada Health GmbH, Karl-Liebknecht-Str. 1, 10178 Berlin, Germany.
81. College of Health, Well-being and Life-Sciences, Sheffield Hallam University, Sheffield, UK.
82. Advanced Wellbeing Research Centre, Sheffield Hallam University, Olympic Legacy Park, 2 Old Hall Road, Sheffield, S9 3TU.
83. Dept of Genetics, Assistance Publique-Hôpitaux de Paris - Université de Paris, Robert DEBRE University Hospital, 48 bd SERURIER, Paris, France.
84. INSERM UMR 1141 "NeuroDiderot", Hôpital Robert DEBRE, Paris, France.
85. Department of Genetics, Assistance Publique-Hôpitaux de Paris - Sorbonne Université, Pitié-Salpêtrière University Hospital, 83 Boulevard de l'Hôpital, Paris, France.
86. Reference center of rare diseases "intellectual disability of rare causes", Paris, France.
87. Institut du Cerveau (ICM), UMR S 1127, Inserm U1127, CNRS UMR 7225, Sorbonne Université, 75013, Paris, France.
88. Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
89. Genetic Medicine Division, University Hospitals and University of Geneva, Geneva, Switzerland.
90. Genetics & Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
91. Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada.
92. Paediatric Neurology, University Hospital Galway.
93. Institute of Rare Diseases Research, Spanish Undiagnosed Rare Diseases Cases Program (SpainUDP) & Undiagnosed Diseases Network International (UDNI), Instituto de Salud Carlos III, Madrid, Spain.
94. Neuroscience Department, Children's Hospital A. Meyer-University of Florence, 50139, Florence, Italy.
95. Institute of Genomic Medicine and Rare Diseases, Semmelweis University, Budapest, Hungary.
96. Koç University, School of Medicine, Translational Medicine Research Center, KUTTAM-NDAL Istanbul Turkey.
97. Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.

98. Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain.
99. Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
100. Centre de Génétique Humaine, Institut de Pathologie et de Génétique, Gosselies, Belgium.
101. School of Pharmacy and Bimolecular Sciences, RCSI, Dublin, Ireland.
102. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
103. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
104. Neurology / Neurogenetics Laboratory University of Crete, Heraklion, Crete, Greece.
105. Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
106. St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
107. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
108. Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
109. St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
110. SFI FutureNeuro Research Centre, Dublin, Ireland.
111. Department of Paediatrics, RCSI, Ireland.
112. Department of Paediatrics Neurology, CHI, Dublin, Ireland.
113. Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany.
114. RESIST – Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Germany.
115. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
116. Catalan Institute of Oncology (IROCA), Barcelona, Spain.
117. Pediatric Neurology Department, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.
118. SFI Centre for Research Training in Genomics Data Science, Ireland.
119. Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
120. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
121. Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
122. Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
123. Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
124. Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.
125. Diagnostic Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
126. Immunology Division, Genetics Department. Vall d'Hebron University Hospital (HUVH), Barcelona, Spain.
127. Immunology Unit. Department of Cell Biology, Physiology and Immunology. Autonomous University of Barcelona (UAB), Bellaterra, Spain.
128. Department of Neurology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
129. Département de néphrologie, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
130. Department of Neurology, Beaumont Hospital, Dublin, Ireland.
131. Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
132. Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France.
133. Department of Neurology, CUB Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
134. Program for Undiagnosed Rare Diseases (UD-ProZA), Ghent University Hospital, Ghent, Belgium.
135. Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

136. Neuromuscular Disorders Unit , Department of Pediatric Neurology. Hospital Sant Joan de Déu, Barcelona, Spain
137. Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
138. Saint Luke Hospital, Division of Child Neurology, Thessaloniki, Greece.
139. Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy.
140. Medical Genetics, University of Siena, Italy.
141. School of Computation, Information and Technology, Technical University of Munich, Garching, Germany.
142. Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany.
143. Computational Health Center, Helmholtz Center Munich, Neuherberg, Germany.
144. Department of Clinical Genetics, CHI, Dublin, Ireland.
145. Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany.
146. Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany.
147. DZIF – German Center for Infection Research, Satellite Center Freiburg, Germany.
148. CIBSS – Centre for Integrative Biological Signalling Studies, Albert-Ludwigs University, Freiburg, Germany.
149. Neurofarba Department, University of Florence, Florence, Italy.
150. Folkhälsan Research Centre and Medicum, University of Helsinki, Helsinki, Finland.
151. Dpt. of Neurology, Ghent University Hospital, Ghent, Belgium.
152. Institute of Systems Motor Science, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
153. Department of Neurology, University Hospital Schleswig Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany.
154. Medizinische Klinik und Poliklinik IV – Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
155. Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
156. Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
157. Clinical Bioinformatics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
158. Neurochemistry and Biomarker Unit, 1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece.
159. Institute of Human Genetics, University Hospital of Cologne, University Cologne, Kerpener Str. 34, 50931 Cologne, Germany.
160. Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany.
161. Institute for Genetics, University of Cologne, 50674 Cologne, Germany.
162. Center for Rare Diseases Cologne, University Hospital Cologne, 50937, Cologne, Germany.
163. Pediatric Neurology Unit, University Hospitals, Geneva, Switzerland.
164. Univ. Bordeaux, MRGM INSERM U1211, CHU de Bordeaux, Service de Génétique Médicale , F-33000 Bordeaux, France.
165. MGZ - Medical Genetics Center, Munich, Germany.
166. Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
167. Institute of Pathology and Genetics, Charleroi, Belgium.
168. Department of Neuropediatrics and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

169. Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
170. Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
171. Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, Spain.
172. Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Slovenia.
173. Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
174. Département de Médecine, Université de namur (Unamur), Namur, Belgique.
175. Center for Rare Diseases, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23562, Lübeck, Germany.
176. Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
177. Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII.
178. East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
179. Department of Paediatrics, University of Cambridge, Cambridge, UK.
180. Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy.
181. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
182. Department of Pediatric Neurology, Developmental Neurology and Social Pediatrics, Children's Hospital University of Essen, Essen, Germany.
183. Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
184. Center for Personalized Oncology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
185. Pediatric Neurology and Muscular Disease Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
186. 1st Department of Neurology, Aristotle University of Thessaloniki, University General Hospital of Thessaloniki, AHEPA, Thessaloniki, Greece.
187. IRCCS Istituto Giannina Gaslini, Genoa, Italy.
188. Human Genetics Department, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.
189. Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, CHU Bordeaux – Hôpital Pellegrin, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France.
190. Tampere Neuromuscular Center, Tampere, Finland.
191. Vasa Central Hospital, Vaasa, Finland.
192. Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

'Solve-RD DITF-ITHACA'

Kristin M. Abbott¹, Rami Abou Jamra², Siddharth Banka^{3,4}, Tobias Bartolomaeus², Ange-Line Bruel^{5,6}, Lucia Pia Bruno^{7,8}, Patrick Callier⁶, Michele Carullo^{7,8}, Andrea Ciolfi⁹, Jill Clayton-Smith^{3,4}, Victor Couturier⁵, Bruno Dallapiccola⁹, Elke de Boer^{10,11}, Jean-Madeleine de Sainte Agathe¹², Anne-Sophie Denommé-Pichon^{5,6}, Christel Depienne^{13,14}, Séverine Drunat^{15,16}, Yannis Duffourd^{5,6}, Andreas Dufke¹⁷, Laurence Faivre^{6,18-21}, Chiara Fallerini^{7,8}, Tobias B. Haack¹⁷, Marketa Havlovicova²², Delphine Heron^{12,23}, Adam Jackson^{3,4}, Boris Keren¹², Mieke Kerstjens¹, Tjitske Kleefstra^{10,11}, Didier Lacombe^{24,25}, Caterina Lo Rizzo²⁶, Estrella López Martín²⁷, Milan Macek Jr.²², Francesca Mari^{7,8,26}, Beatriz Martínez Delgado²⁷, Isabelle Maystadt²⁸, Maria Antonietta Mencarelli²⁶, Cyril Mignot^{12,13}, Manuela Morleo²⁹, Vincenzo Nigro^{29,30}, Machteld Oud^{10,11}, Joohyun Park¹⁷, Christophe Philippe^{5,6}, Michele Pinelli²⁹, Simone Pizzi⁹, Konrad Platzer², Manuel Posada²⁷, Francesca C. Radio⁹, Alessandra Renieri^{7,8,26}, Olaf Riess^{17,31}, Caroline Rooryck^{24,25}, Lukas Ryba²², Hana Safraou^{5,6}, Gijs W.E. Santen³², Miroslav Stofa²², Marco Tartaglia⁹, Christel Thauvin^{6,18-21}, Annalaura Torella³⁰, Frédéric Tran Mau-Them^{5,6}, Aurélien Trimouille^{24,25}, Alain Verloes^{15,16}, Lisenka Vissers^{10,11}, Antonio Vitobello^{5,6}, Pavel Votykpa²², Roberta Zeuli³⁰ and Kristina Zguro⁷.

Affiliations

1. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
2. Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
3. Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK.
4. Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
5. Dijon University Hospital- UF innovation en diagnostic génomique, Dijon, France.
6. Inserm - University of Burgundy-Franche Comté, UMR1231 GAD, Dijon, France.
7. Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy.
8. Medical Genetics, University of Siena, Italy.
9. Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
10. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
11. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
12. Department of Genetics, Assistance Publique-Hôpitaux de Paris - Sorbonne Université, Pitié-Salpêtrière University Hospital, 83 Boulevard de l'Hôpital, Paris, France.
13. Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, Inserm U1127, CNRS UMR 7225, F-75013 Paris, France.
14. Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
15. Dept of Genetics, Assistance Publique-Hôpitaux de Paris - Université de Paris, Robert DEBRE University Hospital, 48 bd SERURIER, Paris, France.
16. INSERM UMR 1141 "NeuroDiderot", Hôpital Robert DEBRE, Paris, France.
17. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
18. Dijon University Hospital, Centre of Reference for Rare Diseases: Development disorders and malformation syndromes, Dijon, France.
19. Dijon University Hospital, FHU-TRANSLAD, Dijon, France.
20. Dijon University Hospital, Genetics Department, Dijon, France.
21. Dijon University Hospital, GIMI institute, Dijon, France.

22. Department of Biology and Medical Genetics, Charles University Prague-2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
23. Reference center of rare diseases "intellectual disability of rare causes", Paris, France.
24. MRGM, Maladies Rares: Génétique et Métabolisme, INSERM U1211, Université de Bordeaux, Bordeaux, France.
25. Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
26. Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy.
27. Institute of Rare Diseases Research, Spanish Undiagnosed Rare Diseases Cases Program (SpainUDP) & Undiagnosed Diseases Network International (UDNI), Instituto de Salud Carlos III, Madrid, Spain.
28. Centre de Génétique Humaine, Institut de Pathologie et de Génétique, Gosselies, Belgium.
29. Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
30. Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Italy.
31. Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.
32. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

'Solve-RD DITF-RND'

Jonathan Baets¹⁻³, Peter Balicza⁴, Selina Banu⁵, Ayşe Nazlı Başak⁶, Danique Beijer⁷, Frederik Braun⁸, Elisa Cali⁵, Ana Laura Cazorro⁹, Viorica Chelban⁵, Patrick Chinnery^{10, 11}, Giulia Coarelli¹², Jonathan de Winter¹⁻³, Bart Dermaut¹³⁻¹⁵, Minas Drakos¹⁶, Alexandra Dürr¹⁷⁻²¹, Stephanie Efthymiou⁵, Lisa-Marie Erlandsson^{22, 23}, Fei Gao¹⁰, Holm Graessner^{24, 25}, Lena Guillot-Noel¹², Tobias Haack²⁴, Michael G. Hanna⁵, Dimitri Hemelsoet^{14, 26}, Holger Hengel^{22, 23}, Rebecca Herzog^{27, 28}, Peter Heutink^{22, 23}, Rita Horvath¹⁰, Henry Houlden⁵, Erik-Jan Kamsteeg²⁹, Josua Kegele³⁰, Melanie Kellner^{22, 23}, Christoph Kessler^{22, 23}, Evgenia Kokosali¹⁶, Ingrid Kolen³¹, Holger Lerche³⁰, Katja Lohmann³², Alfons Macaya^{9, 33}, Francesca Magrinelli³⁴, Anna Marce Grau⁹, Ales Maver³⁵, Judit Molnar⁴, Heba Morsy^{5, 36}, Alexander Münchau²⁷, Juan Dario Ortigoza-Escobar³⁷⁻³⁹, Martje G. Pauly^{27, 28, 32}, Borut Peterlin³⁵, Martin Regensburger⁴⁰, Selina Reich^{7, 23}, Olaf Riess^{24, 25}, Jonathan Rohrer⁴¹, Vincenzo Salpietro⁵, Ulrike Schara-Schmidt⁸, Ludger Schöls^{22, 23}, Nika Schuermans¹³⁻¹⁵, Rebecca Schüle^{22, 31}, Giovanni Stevanin^{17-19, 21, 42}, Tipu Sultan⁵, Matthis Synofzik^{7, 23}, Huma Tariq⁵, Vincent Timmerman^{2, 43}, Liedewei van de Vondel^{1, 2, 43}, Bart van de Warrenburg^{44, 45}, Nienke van Os^{44, 45}, Jana Vandrovцова⁵, Hannah Verdin¹³, Edgard Verdura⁹, Sarah Wiethoff⁵, Carlo Wilke^{7, 23}, Jürgen Winkler⁴⁰, Jishu Xu²²⁻²⁴, Ioannis Zaganas¹⁶.

Affiliations

1. Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium.
2. Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium.
3. Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium.
4. Institute of Genomic Medicine and Rare Diseases, Semmelweis University, Budapest, Hungary.
5. Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
6. Koç University, School of Medicine, Translational Medicine Research Center, KUTTAM-NDAL Istanbul Turkey.
7. Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
8. Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, Essen, Germany.
9. Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
10. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
11. Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
12. Institut du Cerveau, INSERM U1127, CNRS UMR7225, Sorbonne university, Paris, France
13. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
14. Program for Undiagnosed Rare Diseases (UD-ProZA), Ghent University Hospital, Ghent, Belgium.
15. Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
16. Neurology / Neurogenetics Laboratory University of Crete, Heraklion, Crete, Greece.
17. Institut National de la Santé et de la Recherche Médicale (INSERM) U1127, Paris, France.
18. Centre National de la Recherche Scientifique, Unité Mixte de Recherche (UMR) 7225, Paris, France.
19. Unité Mixte de Recherche en Santé 1127, Université Pierre et Marie Curie (Paris 06), Sorbonne Universités, Paris, France.
20. Centre de Référence de Neurogénétique, Hôpital de la Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
21. Institut du Cerveau - ICM, Paris, France.

22. Department of Neurodegeneration, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
23. German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
24. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
25. Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.
26. Dpt. of Neurology, Ghent University Hospital, Ghent, Belgium.
27. Institute of Systems Motor Science, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
28. Department of Neurology, University Hospital Schleswig Holstein, Ratzeburger Allee 160, 23562, Lübeck, Germany.
29. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
30. Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
31. Division of Neurodegenerative Diseases and Movement Disorders, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
32. Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
33. Institute of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain.
34. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, WC1N 3BG.
35. Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Slovenia.
36. Department of Human Genetics, Medical Research Institute, Alexandria University, Egypt.
37. U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, Barcelona, Spain.
38. Movement Disorders Unit, Department of Child Neurology, Institut de Recerca Sant Joan de Déu.
39. European Reference Network for Rare Neurological Diseases (ERN-RND), Barcelona, Spain.
40. Department of Molecular Neurology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
41. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
42. Ecole Pratique des Hautes Etudes, Paris Sciences et Lettres Research University, Paris, France.
43. Peripheral Neuropathy Research Group, University of Antwerp, Antwerp, Belgium.
44. Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
45. Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

'Solve-RD DITF-EURO-NMD'

Özge Aksel-Kiliçarslan¹, Jonathan Baets²⁻⁴, Rabah Ben Yaou^{5,6}, Gisèle Bonne⁵, Enrico Bugiardini⁷, Ana Casasús⁸, Patrick F Chinnery^{9,10}, Kristl Claeys^{11,12}, Enzo Cohen⁵, Mireille Cossee^{13,14}, Judith Cossins¹⁵, Laura Costa¹⁶, Jonathan de Winter²⁻⁴, Jordi Diaz Manera¹⁷, Berta Estevez^{18,19}, Teresinha Evangelista⁵, Alessandra Ferlini²⁰, Andrea Gangfuss²¹, Fei Gao⁹, David Gómez¹⁶, Nora Gómez Lasarte²², Peter Hackman²³, Rita Horvath⁹, Henry Houlden⁷, Mridul Johari²³, Danny Jomaa²⁴, Mert Karakaya²⁵⁻²⁸, Jarred Lau¹, Hanns Lochmüller^{1,29,30}, Adolfo López de Munain Arregui²², Will Macken³¹, Chiara Marini-Bettolo¹⁷, Pilar Marti⁸, Manuela Morleo^{32,33}, Juliane Müller³¹, Francina Munell¹⁶, Francesco Muntoni³¹, Francesco Musacchia^{32,33}, Andres Nacimiento Osorio¹⁸, Daniel Natera¹⁸, Isabelle Nelson⁵, Vincenzo Nigro^{32,33}, Catarina Olimpo³⁴, Aurelien Perrin^{13,14}, Luke Perry³¹, Giulio Piluso³², Michele Pinelli^{33,35}, Veronica Pini³¹, Rob Pitceathly³¹, Kiran Polavarapu¹, Alessia Pugliese¹, Penelope Romero¹⁶, Andreas Roos^{1,21,36}, Amets Saenz Pena²², Manuela Santos³⁷, Anna Sarkozy³¹, Marco Savarese²³, Rita Selvatici²⁰, Malaichamy Sivasankar¹, Volker Straub¹⁷, Rachel Thompson¹, Vincent Timmerman^{3,38}, Ana Topf¹⁷, Annalaura Torella^{32,33}, Bjarne Udd^{23,39,40}, Liedewei van de Vondel^{2,3,38}, Charles van Goethem¹³, Jana Vandrovцова⁷, Alessandra Varavallo³³, Juan J Vilchez⁸, Brunhilde Wirth²⁵⁻²⁸, Irina Zaharieva³¹, Miren Zulaica²².

Affiliations

1. Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada.
2. Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium.
3. Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerpen, Belgium.
4. Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium.
5. Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, F-75013 Paris, France.
6. Service des bases de données, Institut de Myologie, F-75013 Paris, France.
7. Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
8. Health Research Institute Hospital La Fe, Valencia, Spain.
9. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
10. Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
11. Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
12. Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.
13. Laboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire de Montpellier, 34093 Montpellier, France
14. PhyMedExp, Université de Montpellier, INSERM, CNRS, 34093 Montpellier, France.
15. Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
16. Pediatric Neurology Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
17. John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
18. Neuromuscular Disorders Unit, Department of Pediatric Neurology. Hospital Sant Joan de Déu, Barcelona, Spain
19. Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
20. Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Italy.

21. Department of Pediatric Neurology, Developmental Neurology and Social Pediatrics, Children's Hospital University of Essen, Essen, Germany.
22. Hospital Universitario Donostia, San Sebastián, Spain.
23. Folkhälsan Research Centre and Medicum, University of Helsinki, Helsinki, Finland.
24. Queen's School of Medicine, Queen's University, Kingston, Ontario, Canada.
25. Institute of Human Genetics, University Hospital of Cologne, University Cologne, Kerpener Str. 34, 50931 Cologne, Germany.
26. Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany.
27. Institute for Genetics, University of Cologne, 50674 Cologne, Germany.
28. Center for Rare Diseases Cologne, University Hospital Cologne, 50937, Cologne, Germany.
29. Department of Neuropediatrics and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
30. Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
31. Dubowitz Neuromuscular Centre, UCL Great Ormond Street Hospital, London, UK.
32. Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Napoli, Italy.
33. Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
34. Department of Clinical Genetics, Cambridge University Hospital, Cambridge, UK.
35. Università di Napoli Federico II, Napoli, Italy.
36. Department of Neurology, Heimer Institute for Muscle Research, University Hospital Bergmannsheil, Ruhr-University Bochum, 44789 Bochum, Germany.
37. Centro Hospitalar Universitário do Porto, Porto, Portugal.
38. Peripheral Neuropathy Research Group, University of Antwerp, Antwerp, Belgium.
39. Tampere Neuromuscular Center, Tampere, Finland.
40. Vasa Central Hospital, Vaasa, Finland.

‘Solve-RD DITF-GENTURIS’

Stefan Aretz^{1, 2}, Gabriel Capella^{3, 4}, Sérgio Castedo⁵⁻⁸, Richarda de Voer^{9, 10}, Gareth Evans¹¹, Susana Fernandes¹², José Garcia-Pelaez^{5, 6}, Luzia Garrido⁸, Elke Holinski-Feder^{13, 14}, Nicoline Hoogerbrugge^{9, 10}, David Huntsman^{15, 16}, Arne Jahn^{17, 18}, C. Marleen Kets^{9, 10}, Andreas Laner¹⁴, Marjolijn Ligtenberg^{9, 10, 19}, Nelson Martins^{5, 6}, Andrea Meinhardt¹⁷, Arjen Mensenkamp^{9, 10}, Carla Oliveira⁵⁻⁷, Sophia Peters¹, Isabel Quintana³, Evelin Schröck^{17, 18}, Anna Sommer¹, Isabel Spier^{1, 2}, Liesbeth Spruijt^{9, 10}, Verena Steinke-Lange^{13, 14}, Iris te Paske^{9, 10}, Mariona Terradas³, Marc Tischkowitz²⁰, Laura Valle^{3, 4}, Rachel van der Post^{10, 19}, Yasmijn van Herwaarden^{10, 21}, Wendy van Zelst-Stams^{9, 10}, Doreen William^{17, 18}

Affiliations

1. Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
2. Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
3. Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
4. Catalan Institute of Oncology (IROCA), Barcelona, Spain.
5. IPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.
6. i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
7. Faculty of Medicine, University of Porto, Portugal.
8. CHUSJ, Centro Hospitalar e Universitário de São João, Porto, Portugal.
9. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
10. Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
11. Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9WL, UK.
12. Departament of Genetics, Faculty of Medicine, University of Porto, Portugal.
13. Medizinische Klinik und Poliklinik IV – Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
14. MGZ - Medical Genetics Center, Munich, Germany.
15. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
16. British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
17. Institute of Clinical Genetics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
18. National Center for Tumor Diseases (NCT), Dresden, Germany.
19. Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
20. Academic Department of Medical Genetics, Cambridge University, Cambridge, UK.
21. Department of Gastroenterology, Radboud University Medical Center, Nijmegen, the Netherlands.

'Solve-RD DITF-EpiCARE'

Marc Abramowicz^{1, 2}, Nicholas Allen³, Simona Balestrini^{4, 5}, Tobias Bartolomaeus⁶, Ravishankara Bellampalli⁷, Katherine Benson^{8, 9}, Francesca Bisulli^{10, 11}, Christian Boßelmann¹², Susan Byrne^{8, 9}, Laura Canafoglia¹³, Evelina Carapancea¹³, Barbara Castellotti¹⁴, Gianpiero Cavalleri^{8, 9, 15}, Roberta Cilio¹⁶, Norman Delanty^{8, 9, 17}, Christel Depienne¹⁸, Chantal Depondt¹⁹, Sarah Duerinckx¹⁹, Zakaria Eddafir²⁰, Kornelia Ellwanger²¹, Silvana Franceschetti²², Elena Freri²³, Hamidah Ghani^{8, 9, 15}, Tiziana Granata²³, Marie Greally^{8, 9, 24}, Renzo Guerrini^{4, 5}, Tobias B. Haack^{21, 25}, Eva Hammar Bouveret¹, Michele Iacomino²⁶, Rami Jamra⁶, Josua Kegele⁶, Christian Korff²⁷, Roland Krause²⁸, Alma Küchler¹⁸, Robert Lauerer-Braun¹², Damien Lederer²⁹, Elsa Leitão¹⁸, Holger Lerche¹², Gaëtan Lesca^{30, 31}, David Lewis-Smith³², Laura Licchetta¹⁰, Frédéric Masclaux¹, Patrick May²⁸, Davide Mei⁴, Cyril Mignot^{33, 34}, Charissa Millevert^{20, 35}, Raffaella Minardi¹⁰, Patrick Moloney⁷, Hiltrud Muhle³⁶, Mary O Reghan³⁷, Joohyun Park²¹, Elena Parrini⁴, Manuela Pendziwiat^{36, 38}, Konrad Platzner⁶, Johanna Pohl³⁶, Mary Sandrine²⁹, Marcello Scala^{26, 39}, Sanjay Sisodiya⁷, Noor Smal²⁰, Hannah Stamberger^{20, 35}, Pasquale Striano^{26, 39}, Roxane van Heurck¹, Christina Vosseler-Wolf²¹, David Webb³⁷, Sarah Weckhuysen^{20, 35, 40}, Federico Zara^{26, 39}.

Affiliations

1. Genetic Medicine Division, University Hospitals and University of Geneva, Geneva, Switzerland.
2. Genetics & Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
3. Paediatric Neurology, University Hospital Galway, Ireland.
4. Neuroscience Department, Meyer Children's Hospital IRCCS, 50139, Florence, Italy.
5. Neurofarba Department, University of Florence, Florence, Italy.
6. Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
7. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
8. School of Pharmacy and Bimolecular Sciences, RCSI, Dublin, Ireland.
9. SFI FutureNeuro Research Centre, Dublin, Ireland.
10. IRCCS Istituto delle Scienze Neurologiche di Bologna, European Reference Network for Rare and Complex Epilepsies (EpiCARE), Bologna, Italy.
11. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna Italy.
12. Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
13. Integrated Diagnostics for Epilepsy, Department of Diagnostic and Technology, European Reference Network EpiCare, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
14. Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
15. SFI Centre for Research Training in Genomics Data Science, Ireland.
16. Division of Pediatric Neurology, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium.
17. Department of Neurology, Beaumont Hospital, Dublin, Ireland.
18. Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
19. Department of Neurology, CUB Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
20. VIB-CMN, Applied and Translational Neurogenomics Group, University of Antwerp, Antwerpen, Belgium.
21. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
22. Neurophysiopathology, European Reference Network EpiCare, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

23. Department of Paediatric Neuroscience, European Reference Network EPIcare, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
24. Department of Clinical Genetics, CHI, Dublin, Ireland.
25. Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.
26. IRCCS Istituto Giannina Gaslini, Genoa, Italy.
27. Pediatric Neurology Unit, University Hospitals, Geneva, Switzerland.
28. Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
29. Institute of Pathology and Genetics, Charleroi, Belgium.
30. Department of Medical Genetics, Lyon University Hospitals, Lyon, France.
31. NEUROMYOGENE INSTITUTE, Laboratoire Physiopathologie et Génétique du Neurone et du Muscle, NEUROMYOGENE INSTITUTE, CNRS UMR 5261 -INSERM U1315, Université de Lyon - Université Claude Bernard Lyon 1.
32. FutureNeuro SFI Research Centre, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
33. Department of Genetics, Assistance Publique-Hôpitaux de Paris - Sorbonne Université, Pitié-Salpêtrière University Hospital, 83 Boulevard de l'Hôpital, Paris, France.
34. Institut du Cerveau (ICM), UMR S 1127, Inserm U1127, CNRS UMR 7225, Sorbonne Université, 75013, Paris, France.
35. Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerpen, Belgium.
36. Department of Neuropaediatrics, University Medical Centre Schleswig-Holstein and Christian-Albrechts-University of Kiel, Kiel, Germany.
37. Department of Paediatrics Neurology, CHI, Dublin, Ireland.
38. Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
39. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
40. Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Belgium.

‘Solve-RD DITF-RITA’

Kristin Abbott¹, Laura Batlle-Masó^{2,3}, Kaan Boztug^{4,6}, Andres Caballero Garcia de Oteyza⁷, Isabella Ceccherini⁸, Roger Colobran^{9, 10}, Virgil Dalm^{11, 12}, Pavla Doležalová¹³, Karin Engelhardt¹⁴, Marco Gattorno¹⁵, Bodo Grimbacher^{7, 16-19}, Matthias Haimel⁴, Sophie Hambleton¹⁴, Alexander Hoischen²⁰⁻²², Iris Hollink²³, Manon Huibers²⁴, Raul Jimenez Heredia^{4, 6}, Anne Sophie Korganow²⁵, Helen Leavis²⁶, Kars Maassen²⁷, Lisette Meerstein-Kessel²³, Lotte Pape¹, Giada Recchi¹⁵, Marta Rusmini²⁸, Abraham Rutgers¹, Anna Segarra Roca⁴, Annet Simons²⁰, Paolo Uva²⁸, Frank van de Veerdonk^{21, 22}, Caspar van der Made²⁰⁻²², Lars van der Veken²⁴, Marielle van Gijn^{1, 29}, Joris van Montfrans³⁰, Erika Van Nieuwenhove³⁰, Clementien Vermont³¹, Emil Vorsteveld^{20, 22}, Evelien Zonneveld-Huijssoon¹.

Affiliations

1. Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
2. Infection and Immunity in Pediatric Patient, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain.
3. Pediatric Infectious Diseases and Immunodeficiencies Unit, Children’s Hospital. Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Catalonia, Spain.
4. St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria.
5. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
6. Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
7. Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany.
8. Laboratory of Genetics and Genomics of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
9. Translational Immunology Research Group, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain.
10. Immunology Division, Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Catalonia, Spain.
11. Department of Internal Medicine, division of Allergy & Clinical Immunology, Erasmus UMC, Rotterdam, the Netherlands.
12. Department of Immunology, Erasmus UMC, Rotterdam, the Netherlands.
13. Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic.
14. Primary Immunodeficiency Group, Translational and Clinical Research Institute, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
15. Rheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
16. Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Germany.
17. DZIF – German Center for Infection Research, Satellite Center Freiburg, Germany.
18. CIBSS – Centre for Integrative Biological Signalling Studies, Albert-Ludwigs University, Freiburg, Germany.
19. RESIST – Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Germany.
20. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
21. Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands.
22. Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
23. Department of Clinical Genetics, Erasmus UMC, Rotterdam, the Netherlands.
24. Department of Genetics, Division Laboratories, Pharmacy and Biomedical Genetics, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

25. Strasbourg University Hospital, Strasbourg, France.
26. Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
27. Department of Genetics, Genomics Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
28. Clinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
29. Department of Human Genetics, Amsterdam UMC, University of Amsterdam, the Netherlands.
30. Department of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
31. Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus UMC, Rotterdam, the Netherlands.